This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Algarté, M.
Right arrow Articles by Hiscott, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Algarté, M.
Right arrow Articles by Hiscott, J.

 Previous Article  |  Next Article 

Journal of Virology, April 1999, p. 2694-2702, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Ikappa B-Mediated Inhibition of Virus-Induced Beta Interferon Transcription

Michèle Algarté,1,2 Hannah Nguyen,1,3 Christophe Heylbroeck,1,3 Rongtuan Lin,1,2 and John Hiscott1,2,3,*

Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital,1 and Departments of Microbiology3 and Medicine,2 McGill University, Montreal, Quebec, Canada H3T 1E2

Received 2 September 1998/Accepted 10 December 1998


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

We have examined the consequences of overexpression of the Ikappa Balpha and Ikappa Bbeta inhibitory proteins on the regulation of NF-kappa B-dependent beta interferon (IFN-beta ) gene transcription in human cells after Sendai virus infection. In transient coexpression studies or in cell lines engineered to express different forms of Ikappa B under tetracycline-inducible control, the IFN-beta promoter (-281 to +19) linked to the chloramphenicol acetyltransferase reporter gene was differentially inhibited in response to virus infection. Ikappa Balpha exhibited a strong inhibitory effect on virus-induced IFN-beta expression, whereas Ikappa Bbeta exerted an inhibitory effect only at a high concentration. Despite activation of the Ikappa B kinase complex by Sendai virus infection, overexpression of the double-point-mutated (S32A/S36A) dominant repressors of Ikappa Balpha (TD-Ikappa Balpha ) completely blocked IFN-beta gene activation by Sendai virus. Endogenous IFN-beta RNA production was also inhibited in Tet-inducible TD-Ikappa Balpha -expressing cells. Inhibition of IFN-beta expression directly correlated with a reduction in the binding of NF-kappa B (p50-RelA) complex to PRDII after Sendai virus infection in Ikappa Balpha -expressing cells, whereas IFN-beta expression and NF-kappa B binding were only slightly reduced in Ikappa Bbeta -expressing cells. These experiments demonstrate a major role for Ikappa Balpha in the regulation of NF-kappa B-induced IFN-beta gene activation and a minor role for Ikappa Bbeta in the activation process.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Human interferons (IFNs) are synthesized by leukocytes, macrophages, and epithelial cells in response to virus infection and other pathogenic stimuli. IFNs induce a group of genes encoding proteins with a broad range of antiviral, immunoregulatory, and growth-suppressive activities (reviewed in reference 47). The regulation of alpha/beta IFN (IFN-alpha and IFN-beta ) transcription has served as an important model for examining the transcriptional mechanisms controlling virus-inducible gene expression (reviewed in reference 20). IFN-beta transcriptional regulation is controlled by the protein-DNA interactions within 110 nucleotides upstream of the intronless structural gene and consisting of multiple overlapping positive and negative regulatory domains. Four positive regulatory domains bind specific members of the NF-kappa B, IRF, and CREB/ATF transcription factors, as well as the chromatin-associated HMGI(Y) proteins in an induction-specific and cooperative manner; a higher-order structure termed the enhanceosome is formed that, via recruitment of the CBP/p300 coactivator, stimulates IFN-beta gene transcription (29). Recently, it has been demonstrated that in cells infected by virus, the newly identified IRF-3 and IRF-7 factors bind to the IFN-beta promoter, together with NF-kappa B and ATF-2/c-Jun. The association of these factors in the IFN-beta enhanceosome is thought to create a new protein-protein interface that interacts with the transcriptional coactivator CBP/p300 proteins in response to virus infection, leading to virus-mediated gene activation (16, 24, 26a, 29, 40, 48).

The PRDII domain (-64 to -55) contains the consensus site 5'-GGGAAATTCC-3' for the binding of NF-kappa B/Rel transcription factors. Heterodimer or homodimer combinations of NF-kappa B play an important role in the regulation of a large variety of genes, including cytokines, immune regulatory genes, receptors, and early genes of several viruses. NF-kappa B binding activity is inducible in most cell types by viruses, double-stranded RNA, cytokines, phorbol esters, and oxygen radicals. NF-kappa B was initially described as a protein complex composed of two subunits (p50 and p65) retained in the cytoplasm by its association with the inhibitor subunits Ikappa B. Induction resulted in the release of the heterodimer p50-p65 by Ikappa B, translocation to the nucleus, and binding to kappa B sites. The DNA binding NF-kappa B and the inhibitory Ikappa B proteins are composed of multiple family members that contribute to the diversity of NF-kappa B-mediated gene regulation (reviewed in references 2, 3, 27, and 46).

Phosphorylation and degradation of Ikappa B are crucial regulatory events in the activation of NF-kappa B DNA binding activity. After inducer-mediated stimulation Ikappa Balpha is phosphorylated within the N-terminal signal response domain at Ser-32 and Ser-36 (6, 7, 43) by the Ikappa B kinase (IKK) (13, 28, 35, 50, 53), ubiquitinated, and subsequently degraded by the 26S proteasome (1, 9, 37). Substitution of Ser-32 and Ser-36 prevents Ikappa Balpha phosphorylation, ubiquitination, and degradation, thus generating nondegrading, transdominant repressors of Ikappa Balpha (6, 8, 42). The C-terminal PEST domain of Ikappa Balpha is involved in the intrinsic stability of the protein, and this region is constitutively phosphorylated by CKII (26, 38).

The inducibility of NF-kappa B is controlled by different Ikappa B proteins, thus providing an additional level of regulation for NF-kappa B-dependent gene transcription. Two well-characterized forms, Ikappa Balpha and Ikappa Bbeta (44, 49), share several common structural features, including conserved N-terminal signal response, ankyrin repeat, and C-terminal PEST domains. However, Ikappa Balpha and Ikappa Bbeta respond differentially to distinct inducers: the level of Ikappa Bbeta is not affected by tumor necrosis factor alpha (TNF-alpha ) or phorbol myristate acetate and, after lipopolysac- charide or interleukin-1 (IL-1) induction, the degradation and resynthesis of Ikappa Bbeta occurs more slowly than Ikappa Balpha (41). Ikappa Bbeta is also resynthesized in stimulated cells as a hypophosphorylated protein which is able to form stable complexes with NF-kappa B in the cytosol (32, 49); however, this interaction fails to mask the nuclear localization sequence and DNA binding domain of NF-kappa B, resulting in NF-kappa B-Ikappa Bbeta complexes in the nucleus. This hypophosphorylated form of Ikappa Bbeta acts as a chaperone, by protecting NF-kappa B from Ikappa Balpha and permitting a prolonged activation of gene transcription by NF-kappa B (39). A model has been proposed for NF-kappa B activation consisting of two overlapping phases: first, a transient phase mediated mainly through Ikappa Balpha and, second, a persistent phase of activation mediated by Ikappa Bbeta (39, 41). Recently, two different isoforms of Ikappa Bbeta , Ikappa Bbeta 1 (43 kDa) and Ikappa Bbeta 2 (41 kDa), generated as a consequence of RNA processing and differing in their C-terminal PEST domains, have been identified. The relative amounts of these two forms and their degradation in response to stimulation appears to be cell-type specific. Both Ikappa Bbeta 1 and Ikappa Bbeta 2 bind to the same NF-kappa B subunits and are constitutively phosphorylated (19). Furthermore, Ikappa Balpha is a stronger inhibitor of NF-kappa B activity than Ikappa Bbeta ; the inhibitory activity of Ikappa Bbeta is facilitated on promoters containing HMGI(Y) binding regions (44).

In the present study, the consequences of overexpression of the Ikappa Balpha and Ikappa Bbeta inhibitory proteins on the regulation of NF-kappa B-dependent IFN-beta gene transcription after Sendai virus infection was examined. In transient coexpression studies and in stable tetracycline-inducible human 293 cells, wild-type Ikappa Balpha decreased IFN-beta promoter activity, whereas Ikappa B forms with the S32/36A point mutations completely abolished IFN-beta gene expression. Ikappa Bbeta overexpression had minimal effects on IFN-beta promoter activity. Analysis of NF-kappa B protein-DNA complexes in Ikappa B-expressing cells revealed quantitative and temporal alterations in the patterns of NF-kappa B binding to the PRDII domain after Sendai virus infection. These studies demonstrate differential regulation of IFN-beta transcription by Ikappa Balpha and Ikappa Bbeta and indicate a major role for Ikappa Balpha but not Ikappa Bbeta in IFN-beta regulation.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Generation of plasmids. For transient transfections, wild-type human Ikappa Balpha (wtIkappa Balpha ) or mutated human Ikappa Balpha cDNA was inserted downstream of the simian virus 40 promoter in the pSVK3 vector (Pharmacia Biotech, Uppsala, Sweden) (5). cDNA encoding Ikappa Bbeta (a kind gift from Dimitris Thanos) was inserted into SVK3 between the sites EcoRI and XhoI. Mutated human Ikappa Balpha cDNA was generated as previously described (26). In Ikappa Balpha (2N), serine 32 and serine 36 are replaced by alanine; in Ikappa Balpha (3C) serine 283, threonine 291, and threonine 299 were substituted by an alanine residue, and in Ikappa Balpha -Delta 4 22 amino acids were deleted from the terminal end. 2N+3C and 2NDelta 4 were combinations of the above plasmids. Constructs for the establishment of stable cell line CMVt-rtTA, CMVt-wtIkappa Balpha , and Ikappa Balpha mutants were generated as previously described (5, 25). cDNA encoding Ikappa Bbeta (a kind gift of D. Thanos) was inserted into pCMVt-neo vector (4) at the NotI site.

Cell culture and generation of Ikappa B cell lines. Human 293 cells were cultured in alpha Dulbecco modified Eagle medium (alpha-MEM) supplemented with 10% heat-inactivated fetal bovine serum, glutamine, and antibiotics. CMVt-rtTA 293 cells (26) were cultured in the same medium containing 2.5 ng of puromycin (Sigma) per µl. CMVt-based plasmids (25) expressing wtIkappa Balpha , Ikappa Balpha mutants, or Ikappa Bbeta were introduced into CMVt-rtTA 293 cells by the calcium phosphate coprecipitation method. Cells were selected at 48 h after transfection in alpha-MEM supplemented with 10% heat-inactivated fetal bovine serum, glutamine, and the antibiotics puromycin (2.5 ng/µl) and G418 (400 µg/ml) (Life Technologies, Inc.). Cell clones resistant to G418 were selected individually after Ikappa B expression levels induced by 1 µg of doxycycline (Dox; Sigma) per ml were examined.

Transfections and CAT reporter gene assays. Subconfluent 293 cells, CMVt-rtTA 293 cells, or CMVt-rtTA-Ikappa B-expressing 293 cells were transfected with the IFN-beta -CAT reporter plasmid, by the calcium phosphate coprecipitation method (17). All of the transfections contained equivalent amounts of DNA standardized with the CMV-B1 vector. In some experiments, cells were infected with Sendai virus (500 hemagglutinating units [HAU]/ml for 90 min). At 24 h after infection (48 h after transfection), cytoplasmic extracts were prepared and the protein concentration was determined by Bradford assay (Bio-Rad). Then, 100 µg of cytoplasmic protein extract was assayed for 2 to 4 h at 37°C as previously described (17). Relative chloramphenicol acetyltransferase (CAT) activity was quantified by scintillation counting of acetylated and nonacetylated chloramphenicol forms.

Western blot analysis. To characterize Ikappa B expression, wtIkappa Balpha and Ikappa Balpha mutants and Ikappa Bbeta -expressing cells were cultured in the presence of Dox for various times. Cells were washed twice with phosphate-buffered saline (PBS) and resuspended in lysis buffer containing 10 mM Tris-Cl (pH 8.0), 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 10 µg of pepstatin, 10 µg of leupeptin, and 10 µg of aprotinin per ml. Whole-cell extracts (20 µg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in a 10% gel. Proteins were transferred to Hybond transfer membrane (Amersham, Cleveland, Ohio). Membrane was blocked in a 5% milk-PBS solution for 1 h at room temperature and probed with anti-Ikappa Balpha (22) or anti-Ikappa Bbeta G-20 against the N-terminal sequences of Ikappa Bbeta 1 and Ikappa Bbeta 2 (Santa Cruz Biotechnology, Inc., Valencia, Calif.) antibody in 5% milk-PBS at a dilution of 1:1,000 overnight at 4°C. Membranes were washed four times with PBS, incubated with peroxidase-conjugated secondary antibodies (KPL, Gaithersburg, Md.) (goat anti-mouse antibody was used to detect Ikappa Balpha , and goat anti-rabbit antibody was used to detect Ikappa Bbeta , each at a dilution of 1:1,000), and visualized with the chemiluminescence detection system as recommended by the manufacturer (NEN-Life Science, Boston, Mass.).

Immunoprecipitation and kinase assay. For the in vitro kinase assay, cells were left untreated, were treated with TNF-alpha (10 ng/ml) for 10 min, or were infected with Sendai virus (80 HAU/ml) for different times as indicated. Cells were washed twice in cold PBS and resuspended in lysis buffer containing 20 mM Tris-Cl (pH 7.5), 200 mM NaCl, 0.5% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM NaF, 0.5 mM PMSF, and 5 µg of leupeptin, 5 µg of pepstatin, and 5 µg of aprotinin per ml. Whole-cell extracts (200 µg) were incubated with 500 ng of anti-IKKalpha antibody H-744 (Santa Cruz) and 30 µl of protein A-Sepharose beads for 2 to 4 h at 4°C. Beads were washed three times with lysis buffer and two times with kinase buffer (50 mM Tris-Cl, pH 8.0; 100 mM NaCl; 2 mM MgCl2; 1 mM sodium orthovanadate; 1 mM NaF; 20 mM beta -glycerophosphate; 1 mM DTT; 0.5 mM PMSF; 5 µg [each] of leupeptin, pepstatin, and aprotinin per ml) and then incubated at 30°C for 30 min in kinase buffer containing 5 µCi of [gamma -32P]ATP and 2 µg of recombinant GST-Ikappa Balpha (amino acids [aa] 1-55) or GST-Ikappa Balpha (aa 1 to 55; S32/36A). Reactions were subjected to SDS-PAGE in a 12% polyacrylamide gel. The gels were dried and subjected to autoradiography.

RNA preparation and RNase protection assay. Total RNA from 293 cells was extracted with the RNeasy Mini-Kit (Qiagen, Valencia, Calif.). Total RNA (5 µg) was subjected to RNase protection analysis by using a human CK3 cytokine multi-probe template set of the RiboQuant Multi-Probe RPA kit (PharMingen, San Diego, Calif.). Labelled fragments protected from RNase digestion and corresponding to IFN-beta mRNA were quantified with the NIH Image 1.60 software package. Values were normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and L32 (housekeeping gene) mRNA levels and then plotted as IFN-beta /GAPDH mRNA ratios. Similar results were obtained in three independent experiments.

Electrophoretic mobility shift assay. Nuclear extracts were prepared as previously described (17). First, 5 µg of nuclear extracts was incubated with 5 µg of poly(dI-dC) (Pharmacia) for 10 min at room temperature in a total volume of nuclear extract buffer containing 0.1% Nonidet P-40. Then, each sample was incubated for 30 min at room temperature in the presence of 100,000 cpm of [gamma -32P]ATP-labeled oligonucleotide probe corresponding to the PRDII domain of the IFN-beta promoter (5'-GGGAAATTCCGGGAAATTCC-3'). Protein DNA complexes were then separated on a 5% native polyacrylamide gel (60:1 cross-link) in 0.2× TBE. In competition analysis, a 200-fold molar excess of unlabelled oligonucleotide was incubated in the presence of poly(dI-dC) with the nuclear extracts for 30 min before the addition of probe to the extracts. To examine the individual proteins present in the complex, polyclonal subunit-specific antisera against NF-kappa B were used as previously described (17).


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Inhibition of IFN-beta promoter activity by Ikappa B overexpression. To examine the effect of Ikappa Balpha and Ikappa Bbeta on IFN-beta promoter activity, 293 cells were cotransfected with a CAT reporter gene driven by the entire IFN-beta promoter from -281 to +19 and different expression plasmids encoding wild-type or mutated Ikappa Balpha and wild-type Ikappa Bbeta (Fig. 1A). Several mutant forms of Ikappa Balpha were examined: Ikappa Balpha -2N, which contains the S32A/S36A double point mutation; Ikappa Balpha -3C, which contains the S283A/T291A/T299A triple point mutation; Ikappa Balpha -Delta 4, which contains a 22-aa deletion in the PEST C-terminal domain; and the combination mutants Ikappa Balpha -2N+3C and Ikappa Balpha -2N+Delta 4. At 24 h posttransfection the cells were infected with Sendai virus (500 HAU/ml), and 24 h later the cells were lysed and submitted to CAT reporter gene assay. Full activation of the IFN-beta promoter corresponding to a 50- to 100-fold stimulation was observed in Sendai virus-infected cells cotransfected with the IFN-beta CAT plasmid (Fig. 1B). Cotransfection of increasing amounts of wtIkappa Balpha expressing plasmid resulted in a concentration-dependent decrease of IFN-beta promoter activity. IFN-beta promoter activity was partially inhibited at low wtIkappa Balpha concentrations (Ikappa Balpha /IFN-beta ratio = 0.25) and completely inhibited at higher levels of wtIkappa Balpha (Ikappa Balpha /IFN-beta ratio = 4). Ikappa Balpha mutants containing the S32A/S36A point mutations (Ikappa Balpha 2N, -2N+Delta 4, and -2N+3C) were strongly inhibitory and almost completely inhibited IFN-beta promoter activity at the Ikappa Balpha /IFN-beta ratio of 0.25. In contrast, overexpression of Ikappa Bbeta was a weak inhibitor of IFN-beta promoter activity, with a less-than-twofold inhibition of IFN-beta activity at a Ikappa Bbeta /IFN-beta ratio of 4.0; complete inhibition of IFN-beta promoter activity was observed at the Ikappa Bbeta /IFN-beta ratio of 8. These initial experiments established that Ikappa Balpha was a stronger inhibitor of IFN-beta gene expression than Ikappa Bbeta ; furthermore the nondegrading transdominant forms of Ikappa Balpha (TD-Ikappa Balpha ) are at least 10-fold more inhibitory than wtIkappa Balpha .


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 1.   (A) Schematic of Ikappa Balpha protein. Mutations of Ikappa Balpha are as indicated: Ikappa Balpha -2N, which contains the S32A/S36A double point mutation; Ikappa Balpha -3C, which contains the S283A/T291A/T299A triple point mutation; Ikappa Balpha -Delta 4, which contains a 22-aa deletion in the PEST C-terminal domain; and the combination mutants Ikappa Balpha -2N+3C and Ikappa Balpha -2N+Delta 4. (B) Ikappa B expression inhibits IFN-beta gene expression. The IFN-beta -CAT reporter plasmid (2.5 µg) was cotransfected together with Ikappa B expression plasmids into 293 cells by the calcium phosphate method. After 24 h the cells were infected by Sendai virus (500 HAU/ml), and after a further 24 h the cells were harvested and assayed for CAT activity by using cytoplasmic extracts (50 to 100 µg for 2 h). The ratio of Ikappa B to IFN-beta -CAT reporter is indicated on the graph. The relative CAT activity is expressed as a percentage of the activity observed after Sendai virus infection with IFN-beta -CAT reporter in the absence of Ikappa B plasmid.

Establishment of human 293 cells inducibly expressing Ikappa Balpha and Ikappa Bbeta transgenes. Human 293 cells constitutively expressing Dox-inducible, reverse-tetracycline-inducible transactivator (rtTA-293) were generated as previously described (25); in a second selection, rtTA-293 cells were established that inducibly expressed wtIkappa Balpha , mutant Ikappa Balpha (-2N, -3C, -2N+3C, -Delta 4, and -2NDelta 4) and wtIkappa Bbeta (Fig. 2). For each construct, 10 to 20 potential clones were expanded individually and screened by immunoblot for protein expression after Dox addition for 48 h. For each Ikappa B construct, at least three inducible clones were selected and utilized for further studies; a representative clone expressing each construct is analyzed for Dox inducibility (Fig. 2A). Clones were also selected for their ability to grow at approximately the same rate as parental 293 cells, since overexpression of different Ikappa Bs decreased cell growth and in some clones induced apoptotic cell death (12). Most clones displayed basal Ikappa B expression prior to Dox addition, detected with the MAD3 antibody (Fig. 2A, lanes 3, 5, 7, 9, 11, and 13) and displayed Dox-inducible transgene expression (Fig. 2A, lanes 4, 6, 8, 10, 12, and 14). Ikappa Bbeta -expressing cells also displayed basal levels of transgene expression (Fig. 2C, lanes 3 and 4).


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 2.   Dox-inducible expression of Ikappa B in rtTA-293 cells. (A) Cells selected for wtIkappa Balpha or TD-Ikappa Balpha expression were induced with Dox for 48 h (+) or not induced (-). (B) Immunoblot analysis of Ikappa Balpha -2N+3C expression after Dox induction for 0 to 96 h. (C) Ikappa Bbeta induced expression by Dox for 48 h (+) or not induced (-). Whole-cell extract (20 µg) prepared from induced or uninduced rtTA-293-, wtIkappa Balpha -, Ikappa Balpha -2N-, Ikappa Balpha -2N+3C-, Ikappa Balpha -2NDelta 4-, and Ikappa Bbeta -expressing cells were subjected to SDS-PAGE and transferred to nitrocellulose membrane. WtIkappa Balpha and Ikappa Balpha mutants were detected with Ikappa Balpha -MAD3-specific antibody (33), and wtIkappa Bbeta was detected with Ikappa Bbeta -specific antibody (Santa Cruz Biotechnology).

The kinetics of Ikappa B transgene induction were characterized at various times after Dox induction, and a representative analysis is shown for the Ikappa Balpha -2N+3C clone (Fig. 2B). This clone possessed basal transgene expression compared to control rtTA-293 cells (compare Fig. 2B, lanes 1 to 3). Between 1 and 3 h after Dox addition, the level of Ikappa Balpha transgene expression increased (Fig. 2B, lanes 3 to 5) and reached a peak at about 12 h after Dox addition; high-level expression remained constant for 96 h postinduction (Fig. 2B, lanes 8 to 11). Each selected cell line possessed a similar expression pattern; Ikappa Balpha transgene expression was detectable before Dox induction but increased strongly and progressively following Dox treatment (Fig. 2B). In subsequent experiments, Dox was added 48 h before Sendai virus infection.

Virus-induced activation of the IKK complex. To examine the kinetics of Sendai virus-induced activation in 293 cells, the induction of Ikappa Balpha phosphorylation by the IKK complex was first examined. Sendai virus infection led to activation of the IKK complex as demonstrated by an in vitro kinase assay with immunoprecipitated IKK and the Ikappa Balpha (aa 1 to 55) protein as substrate; activation of IKK by Sendai virus was similar to the level of activated IKK observed after TNF-alpha stimulation of 293 cells (Fig. 3A, lanes 1 to 3). No phosphorylation was observed when the Ikappa Balpha (aa 1 to 55; S32/36A) substrate was used (Fig. 3A, lanes 4 to 6) indicating the specificity of IKK phosphorylation. The kinetics of virus-induced IKK activation demonstrated that IKK activity was maximal at 3 and 6 h after infection (Fig. 3B, lanes 1 to 4) and subsequently decreased between 9 and 15 h (Fig. 3B, lanes 5 to 7). The kinetics of IKK induction also correlated directly with the phosphorylation and degradation of Ikappa Balpha in virus-infected 293 cells (Fig. 3C). Beginning at 3 h postinfection, a slower-migrating form of phosphorylated Ikappa Balpha was detected (Fig. 3C, lane 3), while at 6 h the phosphorylated form was detected but the amount of Ikappa Balpha decreased by fourfold, reflecting phosphorylation-dependent degradation of Ikappa Balpha (Fig. 3C, lane 4). This kinetic analysis demonstrates that Sendai virus infection of 293 cells leads to activation of the IKK complex and phosphorylation of Ikappa Balpha .


View larger version (40K):
[in this window]
[in a new window]
 
FIG. 3.   Activation of the Ikappa B kinase complex by Sendai virus infection. (A) Strain 293 cells were either left untreated (lanes 1 and 4), treated with TNF-alpha (10 ng/ml) for 10 min (lanes 2 and 5), or infected with Sendai virus (80 HAU/ml) for 8 h (lanes 3 and 6). The Ikappa B kinase complex was immunoprecipitated from whole-cell extracts (200 µg) with the anti-IKKalpha antibody H-744 (Santa Cruz) and assayed for Ikappa Balpha phosphorylation by using recombinant wild-type GST-Ikappa Balpha (aa 1 to 55) (lanes 1 to 3) or mutant GST-Ikappa Balpha (aa 1 to 55; S32/36A) substrate (lanes 4 to 6). (B) Kinetic analysis of Ikappa B kinase activation after Sendai virus infection. Strain 293 cells were infected with Sendai virus for different times as indicated, and the kinase activity was measured as described above. (C) Phosphorylation and degradation of Ikappa Balpha in response to Sendai virus infection. Whole-cell extracts (20 µg) from 293 cells infected with Sendai virus (80 HAU/ml) for different times as indicated were subjected to SDS-PAGE and transferred to nitrocellulose membrane. Ikappa Balpha was detected with a monoclonal anti-Ikappa Balpha antibody. The positions of Ikappa Balpha and phosphorylated Ikappa Balpha are indicated by the arrows.

Detection of IFN-beta synthesis in Ikappa B-expressing cells. To examine IFN-beta inducibility in Ikappa B-expressing cells, total RNA from normal and Sendai virus-infected cells was examined by RNase protection analysis at different times after infection, either with or without Dox addition to increase the level of Ikappa B transgene expression (Fig. 4). In control rtTA-293 cells with or without Dox addition, Sendai virus induced IFN-beta mRNA initially at 6 h (Fig. 4A, lanes 1 to 3 and lanes 8 to 10); the amount of mRNA reached a peak at 12 h and thereafter decreased by 24 h (Fig. 4A, lanes 4 to 7 and lanes 11 to 14). In wtIkappa Balpha -expressing cells, the induced level of IFN-beta was delayed slightly, since only a low level of IFN-beta mRNA was detected at 6 h, but again IFN-beta mRNA reached a peak of expression at 12 h (Fig. 4B, lanes 1 to 7); the virus-induced level of IFN-beta mRNA in wtIkappa B-expressing cells was not significantly reduced compared to rtTA-expressing cells (compare Fig. 4A and B, lanes 3 to 5, and Fig. 5A and B). Dox induction of the wtIkappa Balpha transgene reduced the maximum level of IFN-beta mRNA by approximately twofold (Fig. 4B, lanes 8 to 14, and Fig. 5A and B) relative to rtTA-expressing cells, indicating that wtIkappa B overexpression inhibited but did not completely block IFN-beta mRNA expression. However, strikingly, in Ikappa Balpha 2N-expressing cells only low levels of IFN-beta mRNA were detected at 12 and 16 h after infection (Fig. 4C, lanes 1 to 7), likely reflecting the leakiness of transgene expression in these cells. Further induction of the Ikappa Balpha -2N transgene with Dox treatment completely inhibited IFN-beta mRNA expression (Fig. 4C, lanes 8 to 14, and Fig. 5C), resulting in an almost 100-fold reduction in IFN-beta mRNA levels. Similar low levels of expression were also observed in Ikappa Balpha -2NDelta 4- and -2N+3C-expressing cells with or without Dox addition (data not shown). IFN-beta mRNA was also induced in Ikappa Bbeta -expressing cells at 6 to 16 h after Sendai virus infection (Fig. 4D, lanes 1 to 7); Dox induction of the Ikappa Bbeta transgene resulted in a partial decrease of this gene expression (Fig. 4D, lanes 8 to 14, and Fig. 5D).


View larger version (52K):
[in this window]
[in a new window]
 
FIG. 4.   mRNA expression of IFN-beta in Ikappa Balpha - and Ikappa Bbeta -expressing cells after Sendai virus infection. (A) Total RNA (5 µg) prepared from cells 0 to 48 h after Sendai virus infection was used for RNase protection analysis with the human CK3 cytokine template set of the RiboQuant Multi-Probe RPA kit. Cells lines are indicated at the top of each panel. Panels: A, rtTA-293 cells; B, wtIkappa Balpha -expressing cells; C, Ikappa Balpha -2N-expressing cells; D, Ikappa Bbeta -expressing cells. Where indicated, the cells were pretreated with Dox 48 h prior to Sendai virus infection. As a control, the level of GAPDH is shown.


View larger version (32K):
[in this window]
[in a new window]
 
FIG. 5.   Quantification of IFN-beta mRNA expression. Quantification of RNase protection autoradiographs was obtained by normalizing values to the GAPDH and L32 (housekeeping gene) mRNA levels and plotting the values as IFN-beta /GAPDH mRNA ratios. Panels: A, rtTA-expressing cells; B, wtIkappa Balpha -expressing cells; C, Ikappa Balpha -2N-expressing cells; D, Ikappa Bbeta -expressing cells. Lightly shaded columns, no Dox addition; darkly shaded columns, Dox addition (1 µg/ml) for 48 h.

IFN-beta transcription is inhibited in Ikappa B-expressing cells. Ikappa B-expressing 293 cells were transfected with IFN-beta -CAT reporter construct containing the IFN-beta promoter from -281 to +19; at 24 h after transfection, cells were Sendai virus infected and analyzed at 48 h. Cells, either treated or not treated with Dox, showed the same level of IFN-beta -driven CAT activity, indicating that Dox itself had no effect on IFN-beta induction. However, IFN-beta gene activity was modulated significantly by Dox-induced transgene expression (Fig. 6). wtIkappa Balpha - and wtIkappa Balpha -Delta 4 expressing cells showed a decrease in reporter gene activity after Sendai virus infection, and this activity was reduced by one-half with Dox addition. Also Ikappa Balpha -2N- and Ikappa Balpha -2NDelta 4-expressing cells displayed very low levels of gene activity, which was completely inhibited after expression of the Ikappa Balpha transgene. Finally, 293 cells expressing Ikappa Bbeta did not show a decrease in CAT activity after Dox induction, despite induction of the Ikappa Bbeta transgene.



View larger version (61K):
[in this window]
[in a new window]
 
FIG. 6.   Inhibition of IFN-beta promoter activity in Ikappa B-expressing 293 cells. IFN-beta -CAT reporter plasmid (2.5 µg) was transfected into rtTA-293- and Ikappa B-expressing 293 cells by the calcium phosphate method. After 24 h, cells were infected with Sendai virus (500 HAU/ml) for 90 min as indicated. Cultures were harvested at 48 h posttransfection, and 100 µg of the cytoplasmic extracts was prepared from the various cell lines and assayed for CAT activity for 4 h. As indicated, the cells were treated or not treated with Dox 48 h before transfection. The CAT activity observed with extracts of rtTA cells infected by Sendai virus (20 to 30% acetylation) was taken as the 100% value.

Analysis of PRDII DNA binding activity in Ikappa B-expressing cells. To correlate changes in gene activity with potential changes in NF-kappa B-PRDII complex formation after virus infection, mobility shift analyses were performed with nuclear extracts from rtTA-293 and Ikappa B-expressing cells (Fig. 7). Subunit composition of the protein-DNA complexes was determined with antibodies specific to p50, p65, and c-Rel, since previous experiments demonstrated that these three NF-kappa B subunits constituted the majority of NF-kappa B binding activity on PRDII (17). The specificity of complex formation was controlled by competition with a 200-fold excess of unlabeled PRDII oligonucleotide. For rtTA-293 cells, a specific complex appeared at 6 and at 16 h after Sendai virus infection. Anti-p50 and anti-RelA(p65) antibodies resulted in a prominent shift-up of the inducible complex, demonstrating that the lower complex represented the NF-kappa B p50-p50 homodimer and the upper complex represented the p50-p65 heterodimer (Fig. 7A). With nuclear extracts from wtIkappa B-expressing cells infected with Sendai virus, PRDII protein-DNA complex formation corresponding to p50-p50 homodimers and p50-p65 heterodimers were dramatically reduced in intensity and temporally delayed in appearance until 16 h after infection (Fig. 7B). Similarly, in Ikappa Balpha -2N-expressing 293 cells, NF-kappa B complex formation was inhibited and detected only at 16 h after Sendai virus infection (Fig. 7C). With Ikappa Bbeta -expressing cells, formation of NF-kappa B-PRDII complexes was only slightly reduced at 16 h after infection (Fig. 7D). These results demonstrate that Ikappa Balpha expression interferes both kinetically and quantitatively with the formation of NF-kappa B protein-DNA complexes on the PRDII element of IFN-beta promoter after virus infection.


View larger version (41K):
[in this window]
[in a new window]
 
FIG. 7.   Analysis of PRDII DNA binding activity in Ikappa B-expressing cells. Nuclear extracts were prepared from rtTA-293-expressing (A), wtIkappa Balpha -expressing (B), Ikappa Balpha -2N-expressing (C), and Ikappa Bbeta -expressing (D) cells. Cells were infected by Sendai virus (500 HAU/ml) and harvested at the times indicated. Cells were treated with Dox at 48 h prior to Sendai virus infection. Nuclear extracts were incubated in the presence of 5 µg of poly(dI-dC) for 20 min prior to the addition of radiolabelled PRDII probe. For supershift experiments, NF-kappa B-specific antisera (31) were preincubated in presence of electrophoretic mobility shift assay buffer and poly(dI-dC) prior to the addition of the nuclear extracts.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In this study, the potential inhibitory effects of Ikappa Balpha and Ikappa Bbeta on IFN-beta transcriptional activity were analyzed in transient transfections and in stable 293 cell lines expressing Ikappa B transgenes under Tet-inducible control. In transient-transfection studies, high levels of IFN-beta -CAT reporter gene activity were produced after Sendai virus infection, whereas overexpression of wtIkappa Balpha inhibited IFN-beta transcription in a dose-dependent manner. Overexpression of different mutated forms of Ikappa Balpha , particularly Ikappa Balpha -2N(S32A/S36A), completely blocked IFN-beta transcription even at low levels of basal expression. Ikappa Balpha -3C and -Delta 4 also inhibited IFN-beta transcription more dramatically than wtIkappa Balpha . In contrast, Ikappa Bbeta was a poor inhibitor of IFN-beta transcription, indicating a minimal role for Ikappa Bbeta in the regulation of NF-kappa B-dependent IFN-beta gene expression. Similar results were obtained by measuring IFN-beta mRNA accumulation in Tet-inducible rtTA-293 cells expressing the various Ikappa B transgenes. The inhibition of IFN-beta transcription in Ikappa Balpha - and Ikappa Bbeta -expressing cells correlated directly with the delayed appearance of NF-kappa B-PRDII complex formation after Sendai virus infection. Overexpression of Ikappa Balpha or Ikappa Bbeta impaired NF-kappa B binding at an early stage of infection, and the later appearance of NF-kappa B-PRDII complexes at 16 h in Ikappa Balpha -expressing cells was not sufficient to restore full IFN-beta inducibility. Dox-inducible Ikappa Bbeta expression also resulted in a slightly later appearance of NF-kappa B binding activity (16 h compared to 6 h in control cells) which decreased IFN-beta expression moderately.

The IFN-beta promoter contains multiple overlapping positive and negative regulatory domains that bind specific members of the NF-kappa B, IRF, and ATF transcription factor families in an induction-specific manner, together with the chromatin-associated HMGI(Y) proteins (reviewed in reference 20). Extensive work by the Maniatis and Thanos groups revealed that virus-induced activation of the IFN-beta promoter is due to the assembly of a higher-order transcription enhancer complex called an enhanceosome (15, 16, 24, 29, 40, 44). Transcriptional synergy involved in IFN-beta activation also requires interaction of all transcription factor activation domains with CBP/p300 (14, 21, 23, 29, 54). A novel domain (aa 322 to 458), termed the synergism domain, was identified in RelA; this domain contains a potential leucine zipper domain present in CBP and CBP-interacting proteins. Through this domain, RelA associates with CBP, and this interaction is essential for transcriptional synergy. The activation domains of the IFN-beta transcription factors also interact with CBP in vivo and potentially stabilize the initial association between RelA and CBP. Interestingly, the enhanceosome is able to make contact with components of the basal transcription machinery in vitro (TFIID, TFIIA, TFIIB, and the USA coactivator) (24). Based on these findings, it was proposed that synergistic activation of IFN-beta initially involves simultaneous recruitment of RNA polymerase II and the basal transcriptional machinery by the enhanceosome via CBP recruitment by RelA, implicating CBP as a bridge between transcriptional machinery and the IFN-beta enhancer. Consistent with the enhanceosome model, we were able to interfere with IFN-beta transcription in vivo by preventing the assembly of the complete enhanceosome; continued sequestration of NF-kappa B in the cytoplasm, particularly by the TD-Ikappa Balpha forms, prevented formation of the enhanceosome and activation of IFN-beta transcription.

The Thanos group demonstrated that the Ikappa Bbeta inhibitory activity was facilitated by the interaction of NF-kappa B with HMGI(Y), and a part of their study was based on the analysis of complexes bound on a PRDII probe (44). Our data are complementary with these observations, and in the context of Sendai virus induction in 293 cells, Ikappa Bbeta does not appear to be involved in the control of IFN-beta transcription. A requirement for Ikappa Bbeta -regulated NF-kappa B activity may be unnecessary in the context of IFN-beta activation because of the rapid and transient nature of IFN-beta induction after virus infection. Together with other regulatory protein-DNA interactions, IFN-beta induction occurs within the first 6 to 12 h of infection and then is rapidly repressed.

In response to induction by TNF-alpha or IL-1, the NF-kappa B-inducing kinase activates the IKK complex that directly phosphorylates Ikappa Balpha and Ikappa Bbeta at two amino-terminal serine residues, leading to Ikappa Balpha and Ikappa Bbeta ubiquitination and subsequent degradation by the proteasome (36). It has recently been shown that other IKK-associated proteins, such as NEMO/IKKgamma and IKAP, regulate the IKK complex and are required for the activation by TNF-alpha or IL-1 (11, 34, 51). Mitogen-activated protein kinase kinase kinase 1 (MEKK1) has also been identified as an upstream regulator of the IKK complex (30). HTLVI-Tax protein has recently been shown to activate IKKalpha and IKKbeta , leading to NF-kappa B activation. Furthermore, a dominant negative mutant of NIK blocked Tax induction of NF-kappa B, thus implicating NIK as a critical upstream regulator (10, 18, 45, 52). Although many viruses induce NF-kappa B binding activity, this study demonstrates for the first time the activation of the IKK complex by Sendai virus and the subsequent phosphorylation and degradation of Ikappa Balpha . Strikingly, the kinetics of the IKK activation by Sendai virus temporally reflect not only NF-kappa B induction but also virus-induced activation of IFN-beta mRNA synthesis. At present, the involvement of upstream kinases in the phosphorylation of the IKK complex by Sendai virus remains to be determined.


    ACKNOWLEDGMENTS

This study was supported by grants from the Medical Research Council of Canada. M.A. was supported by a FRSQ Santé fellowship, H.N. and C.H. were supported by FCAR studentships, and R.L. was supported by a Fraser, Monat, and McPherson Scholarship from McGill University. J.H. is a Senior Scientist of the Medical Research Council of Canada.


    FOOTNOTES

* Corresponding author. Mailing address: Lady Davis Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal, Quebec, Canada H3T1E2. Phone: (514) 340-8222, ext. 5265. Fax: (514) 340-7576. E-mail: mijh{at}musica.mcgill.ca.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Baldi, L., K. Brown, G. Franzoso, and U. Siebenlist. 1996. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of Ikappa Balpha . J. Biol. Chem. 271:376-379[Abstract/Free Full Text].
2. Baldwin, A. S., Jr. 1996. The NF-kappa B and Ikappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649-681[Medline].
3. Beauparlant, P., and J. Hiscott. 1996. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7:175-190[Medline].
4. Beauparlant, P., H. Kwon, M. Clarke, R. Lin, N. Sonenberg, M. Wainberg, and J. Hiscott. 1996. Transdominant mutants of Ikappa Balpha block Tat-TNF synergistic activation of HIV-1 expression and virus multiplication. J. Virol. 70:5777-5785[Abstract].
5. Beauparlant, P., R. Lin, and J. Hiscott. 1996. The role of the C-terminal domain of Ikappa Balpha in protein degradation and stability. J. Biol. Chem. 271:10690-10696[Abstract/Free Full Text].
6. Brockman, J. A., D. C. Scherer, T. A. McKinsey, S. M. Hall, X. Qi, W. Y. Lee, and D. W. Ballard. 1995. Coupling of a signal response domain in Ikappa Balpha to multiple pathways for NF-kappa B activation. Mol. Cell. Biol. 15:2809-2818[Abstract].
7. Brown, K., G. Franzoso, L. Baldi, L. Carlson, L. Mills, Y.-C. Lin, S. Gerstberger, and U. Siebenlist. 1997. The signal response of Ikappa Balpha is regulated by transferable N- and C-terminal domains. Mol. Cell. Biol. 17:3021-3027[Abstract].
8. Brown, K., S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist. 1995. Control of Ikappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488[Abstract/Free Full Text].
9. Chen, Z., J. Hagler, V. J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets Ikappa Balpha to the ubiquitin-proteasome pathway. Genes Dev. 9:1586-1597[Abstract/Free Full Text].
10. Chu, Z.-L., J. Didonato, J. Hawiger, and D. W. Ballard. 1998. The Tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates Ikappa B kinases containing IKKalpha and IKKbeta . J. Biol. Chem. 273:15891-15894[Abstract/Free Full Text].
11. Cohen, L., W. J. Henzel, and P. A. Baeuerle. 1998. IKAP is a scaffold protein of the Ikappa B kinase complex. Nature 395:292-296[Medline].
12. DeLuca, C., H. J. Kwon, N. Pelletier, M. A. Wainberg, and J. Hiscott. 1998. NF-kappa B protects HIV-1 infected myeloid cells from apoptosis. Virology 244:27-38[Medline].
13. DiDonato, J. A., M. Hayakawa, D. M. Rothwarf, E. Zandi, and M. Karin. 1997. A cytokine-responsive Ikappa B kinase that activates the transcription factor NF-kappa B. Nature 388:548-554[Medline].
14. Eckner, R. 1996. p300 and CBP as transcriptional regulators and targets of oncogenic events. J. Biol. Chem. 377:685-688.
15. Escalante, C. R., J. Yie, D. Thanos, and A. K. Aggarwal. 1998. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature 391:103-106[Medline].
16. Falvo, J. V., D. Thanos, and T. Maniatis. 1995. Reversal of intrinsic DNA bends in the IFNbeta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83:1101-1111[Medline].
17. Garoufalis, E., I. Kwan, R. Lin, A. Mustafa, N. Pepin, A. Roulston, J. Lacoste, and J. Hiscott. 1994. Viral induction of the human interferon beta promoter: modulation of transcription by NF-kappa B/Rel proteins and interferon regulatory factors. J. Virol. 68:4707-4715[Abstract/Free Full Text].
18. Geleziunas, R., S. Ferrell, X. Lin, Y. Mu, E. Cunningham, M. Grant, Jr., M. Connelly, J. Hambor, K. Marcu, and W. Greene. 1998. Human T-cell leukemia virus type 1 Tax induction of NF-kappa B involves activation of the Ikappa B kinase alpha  (IKKalpha ) and IKKbeta cellular kinases. Mol. Cell. Biol. 18:5157-5165[Abstract/Free Full Text].
19. Hirano, F., M. Chung, H. Tanaka, N. Maruyama, I. Makino, D. Moore, and C. Scheidereit. 1998. Alternative splicing variants of Ikappa Bbeta establish differential NF-kappa B signal responsiveness in human cells. Mol. Cell. Biol. 18:2596-2607[Abstract/Free Full Text].
20. Hiscott, J., H. Nguyen, and R. Lin. 1995. Molecular mechanisms of interferon beta gene induction. Sem. Virol. 6:161-173.
21. Horvai, A. E., L. Xu, E. Korzus, G. Brard, D. Kalafus, T. M. Mullen, D. W. Rose, M. G. Rosenfeld, and C. K. Glass. 1997. Nuclear integration of JAK/STAT and RAS/AP-1 signalling by CBP and p300. Proc. Natl. Acad. Sci. USA 94:1074-1079[Abstract/Free Full Text].
22. Jaffray, E., K. M. Wood, and R. T. Hay. 1995. Domain organization of Ikappa Balpha and the sites of interaction with NF-kappa B p65. Mol. Cell. Biol. 15:2166-2172[Abstract].
23. Kee, B. L., J. Arias, and M. R. Montminy. 1996. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J. Biol. Chem. 271:2373-2375[Abstract/Free Full Text].
24. Kim, T. K., and T. Maniatis. 1998. The mechanism of transcriptional synergy of an in vitro assembled interferon-beta enhanceosome. Mol. Cell. 1:119-129.
25. Kwon, H., N. Pelletier, C. DeLuca, P. Genin, S. Cisternas, R. Lin, M. A. Wainberg, and J. Hiscott. 1998. Inducible expression of Ikappa Balpha repressor mutants interferes with NF-kappa B activity and HIV-1 replication in Jurkat T cells. J. Biol. Chem. 273:7431-7440[Abstract/Free Full Text].
26. Lin, R., P. Beauparlant, C. Makris, S. Meloche, and J. Hiscott. 1996. Phosphorylation of Ikappa Balpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Mol. Cell. Biol. 16:1401-1409[Abstract].
26a. Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996[Abstract/Free Full Text].
27. May, M. J., and S. Ghosh. 1998. Signal transduction through NF-kappa B. Immunol. Today 19:80-88[Medline].
28. Mercurio, F., H. Zhu, B. W. Murray, A. Shevchenko, B. L. Bennett, J. W. Li, D. B. Young, M. Barbosa, and M. Mann. 1997. IKK-1 and IKK-2: cytokine-activated Ikappa B kinases essential for NF-kappa B activation. Science 278:860-866[Abstract/Free Full Text].
29. Merika, M., A. J. Williams, G. Chen, T. Collins, and D. Thanos. 1998. Recruitment of CBP/p300 by the IFNbeta enhanceosome is required for synergistic activation of transcription. Mol. Cell. 1:277-287[Medline].
30. Nemoto, S., J. Didonato, and A. Lin. 1998. Coordinate regulation of Ikappa B kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappa B inducing kinases. Mol. Cell. Biol. 18:7336-7343[Abstract/Free Full Text].
31. Pepin, N., A. Roulston, J. Lacoste, R. Lin, and J. Hiscott. 1994. Subcellular redistribution of HTLV-1-Tax protein by NF-kappa B/Rel transcription factors. Virology 204:706-716[Medline].
32. Phillips, R. J., and S. Ghosh. 1997. Regulation of Ikappa Bbeta in WEHI 231 mature B cells. Mol. Cell. Biol. 17:4390-4396[Abstract].
33. Rodriguez, M. S., I. Michalopoulos, F. Arenzana-Seisdedos, and R. T. Hay. 1995. Inducible degradation of Ikappa Balpha in vitro and in vivo requires the acidic C-terminal domain of the protein. Mol. Cell. Biol. 15:2413-2419[Abstract].
34. Rothwarf, D. M., E. Zandi, G. Natoli, and M. Karin. 1998. IKK-gamma is an essential regulatory subunit of the Ikappa B kinase complex. Nature 395:297-300[Medline].
35. Régnier, C., H. Y. Song, X. Gao, D. V. Goeddel, Z. Cao, and M. Rothe. 1997. Identification and characterization of an Ikappa B kinase. Cell 90:373-383[Medline].
36. Scheidereit, C. 1998. Docking Ikappa B kinases. Nature 395:225-226[Medline].
37. Scherer, D. C., J. A. Brockman, Z. Chen, T. Maniatis, and D. W. Ballard. 1995. Signal-induced degradation of Ikappa Balpha requires site-specific ubiquitination. Proc. Natl. Acad. Sci. USA 92:11259-11263[Abstract/Free Full Text].
38. Schwarz, E., D. Antwerp, and I. Verma. 1996. Constitutive phosphorylation of Ikappa Balpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free Ikappa Balpha . Mol. Cell. Biol. 16:3554-3559[Abstract].
39. Suyang, H., R. Phillips, I. Douglas, and S. Ghosh. 1996. Role of unphosphorylated, newly synthesized Ikappa Bbeta in persistent activation of NF-kappa B. Mol. Cell. Biol. 16:5444-5449[Abstract].
40. Thanos, D., and T. Maniatis. 1995. Virus induction of human IFNbeta gene expression requires the assembly of an enhanceosome. Cell 83:1091-1100[Medline].
41. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh. 1995. Ikappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 80:573-582[Medline].
42. Traenckner, E. B., H. L. Phal, T. Henkel, N. K. Schmidt, S. Wilk, and P. A. Baeuerle. 1995. Phosphorylation of human Ikappa Balpha on serines 32 and 36 controls Ikappa Balpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14:2876-2883[Medline].
43. Traenckner, E. B. M., H. L. Pahl, T. Henkel, K. N. Schmidt, S. Wilk, and P. A. Baeuerle. 1995. Phosphorylation of human Ikappa Balpha on serines 32 and 36 controls Ikappa Balpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14:2876-2883.
44. Tran, K., M. Merika, and D. Thanos. 1997. Distinct functional properties of Ikappa Balpha and Ikappa Bbeta . Mol. Cell. Biol. 17:5386-5399[Abstract].
45. Uhlik, M., L. Good, G. Xiao, E. Harhaj, E. Zandi, M. Karin, and S.-C. Sun. 1998. NF-kappa B-inducing kinase and Ikappa B kinase participate in human T-cell leukemia virus 1 Tax-mediated NF-kappa B activation. J. Biol. Chem. 273:21132-21136[Abstract/Free Full Text].
46. Verma, I. M., J. K. Stevenson, E. M. Schwarz, D. V. Antwerp, and S. Miyamoto. 1995. Rel/NF-kappa B/Ikappa B family: intimate tales of association and dissociation. Genes Dev. 9:2723-2735[Free Full Text].
47. Vilcek, J., and G. Sen. 1996. Interferons and other cytokines, p. 375-399. In B. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven, New York, N.Y.
48. Wathelet, M. G., C. H. Lin, B. S. Parakh, L. V. Ronco, P. M. Howley, and T. Maniatis. 1998. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell. 1:507-518[Medline].
49. Weil, R., C. Laurent-Winter, and A. Israel. 1997. Regulation of Ikappa Bbeta degradation. Similarities to and differences from Ikappa Balpha . J. Biol. Chem. 272:9942-9949[Abstract/Free Full Text].
50. Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel. 1997. Ikappa B kinase-beta : NF-kappa B activation and complex formation with Ikappa B kinase-alpha and NIK. Science 278:866-869[Abstract/Free Full Text].
51. Yamaoka, S., G. Courtois, C. Bessia, S. T. Whiteside, R. Weil, F. Agou, H. E. Kirk, R. J. Kay, and A. Israel. 1998. Complementation cloning of NEMO, a component of the Ikappa B kinase complex essential for NF-kappa B activation. Cell 93:1231-1240[Medline].
52. Yin, M.-J., L. B. Christerson, Y. Yamamoto, Y.-T. Kwak, S. Xu, F. Mercurio, M. Barbosa, M. H. Cobb, and R. B. Gaynor. 1998. HTLV-I Tax protein binds to MEKK1 to stimulate Ikappa B kinase activity and NF-kappa B activation. Cell 93:875-884[Medline].
53. Zandi, E., D. M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin. 1997. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91:243-252[Medline].
54. Zhang, J. J., U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and J. E. Darnell. 1996. Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling. Proc. Natl. Acad. Sci. USA 93:15092-15096[Abstract/Free Full Text].


Journal of Virology, April 1999, p. 2694-2702, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Konrad, A., Wies, E., Thurau, M., Marquardt, G., Naschberger, E., Hentschel, S., Jochmann, R., Schulz, T. F., Erfle, H., Brors, B., Lausen, B., Neipel, F., Sturzl, M. (2009). A Systems Biology Approach To Identify the Combination Effects of Human Herpesvirus 8 Genes on NF-{kappa}B Activation. J. Virol. 83: 2563-2574 [Abstract] [Full Text]  
  • Jiao, P., Tian, G., Li, Y., Deng, G., Jiang, Y., Liu, C., Liu, W., Bu, Z., Kawaoka, Y., Chen, H. (2008). A Single-Amino-Acid Substitution in the NS1 Protein Changes the Pathogenicity of H5N1 Avian Influenza Viruses in Mice. J. Virol. 82: 1146-1154 [Abstract] [Full Text]  
  • Nogalski, M. T., Podduturi, J. P., DeMeritt, I. B., Milford, L. E., Yurochko, A. D. (2007). The Human Cytomegalovirus Virion Possesses an Activated Casein Kinase II That Allows for the Rapid Phosphorylation of the Inhibitor of NF-{kappa}B, I{kappa}B{alpha}. J. Virol. 81: 5305-5314 [Abstract] [Full Text]  
  • Taylor, R. T., Bresnahan, W. A. (2006). Human Cytomegalovirus IE86 Attenuates Virus- and Tumor Necrosis Factor Alpha-Induced NF{kappa}B-Dependent Gene Expression.. J. Virol. 80: 10763-10771 [Abstract] [Full Text]  
  • Recklies, A. D., Ling, H., White, C., Bernier, S. M. (2005). Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes. J. Biol. Chem. 280: 41213-41221 [Abstract] [Full Text]  
  • Grimm, T., Schneider, S., Naschberger, E., Huber, J., Guenzi, E., Kieser, A., Reitmeir, P., Schulz, T. F., Morris, C. A., Sturzl, M. (2005). EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 105: 3263-3269 [Abstract] [Full Text]  
  • Elco, C. P., Guenther, J. M., Williams, B. R. G., Sen, G. C. (2005). Analysis of Genes Induced by Sendai Virus Infection of Mutant Cell Lines Reveals Essential Roles of Interferon Regulatory Factor 3, NF-{kappa}B, and Interferon but Not Toll-Like Receptor 3. J. Virol. 79: 3920-3929 [Abstract] [Full Text]  
  • Andreakos, E., Smith, C., Monaco, C., Brennan, F. M., Foxwell, B. M., Feldmann, M. (2003). Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 101: 983-991 [Abstract] [Full Text]  
  • Sakaue, G., Hiroi, T., Nakagawa, Y., Someya, K., Iwatani, K., Sawa, Y., Takahashi, H., Honda, M., Kunisawa, J., Kiyono, H. (2003). HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses. J. Immunol. 170: 495-502 [Abstract] [Full Text]  
  • Wang, X., Li, M., Zheng, H., Muster, T., Palese, P., Beg, A. A., García-Sastre, A. (2000). Influenza A Virus NS1 Protein Prevents Activation of NF-kappa B and Induction of Alpha/Beta Interferon. J. Virol. 74: 11566-11573 [Abstract] [Full Text]  
  • Genin, P., Algarte, M., Roof, P., Lin, R., Hiscott, J. (2000). Regulation of RANTES Chemokine Gene Expression Requires Cooperativity Between NF-{kappa}B and IFN-Regulatory Factor Transcription Factors. J. Immunol. 164: 5352-5361 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Algarté, M.
Right arrow Articles by Hiscott, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Algarté, M.
Right arrow Articles by Hiscott, J.